Geron flags RYTELO growth, European launch plans
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Geron Corporation told the Stifel 2026 Healthcare Conference that RYTELO, its lower-risk myelodysplastic syndrome treatment, posted fourth-quarter net revenue above $60 million with an expanding prescriber base. The company plans a German launch by year-end 2026 and France in 2027, while discontinuing the IMpactMF trial to concentrate on RYTELO growth and business development.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.